29 results about "Corneal neovascularization" patented technology

The invention provides a nerve growth factor functionalized exosome as well as a preparation method and application thereof. The functionalized exosome can activate a Wnt / beta-catenin signal channel to maintain dryness of corneal limbal stem cells (LSCs) so as to promote corneal epithelium repair, can activate a cAMP signal channel to relieve inflammatory response and promote corneal nerve regeneration, and can be used for treating or relieving corneal chemical burns, including relieving inflammatory response, reducing stromal scar formation and inhibiting corneal neovascularization. Corneal epithelium repair and nerve regeneration are promoted.

The invention provides an anti-inflammatory and anti-vascular bidirectional trapping combined self-luminous power compound based on neutrophil nano-vesicles as well as a preparation method and application thereof, and belongs to the technical field of biological medicine manufacturing. The compound takes a neutrophil nano-vesicle as a carrier, and is also loaded with bis (2, 4, 5-trichlorosalicylic acid n-amyl ester) oxalate (CPPO) and a photosensitizer Ce6, and meanwhile, the surface of the compound is modified with ranibizumab through ketal mercaptan responded by ROS (reactive oxygen species). The compound has the characteristics of trapping anti-inflammatory factors and spontaneously targeting corneal neovascularization diseased regions, Ranibizumab is responsively released on the basis of ROS to be combined with vascular endothelial growth factors, the anti-angiogenesis function is achieved, meanwhile, chemical energy generated by CPPO under the high-oxygen condition stimulates Ce6 to generate singlet oxygen, and therefore the vascular endothelial cell tubulogenesis capacity is inhibited. The invention provides a new means for treatment of eye disease related diseases.

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The present application provides compositions and methods for treatment of ocular inflammatory conditions, dry eye diseases, and abnormal corneal neovascularization, using etiprednol. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, propylene glycol diacetate (PGD), a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, phenethyl alcohol, ethanol, isopropanol, glycerol, propylene glycol, polyethylene glycol, n-butanol, or combinations thereof. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of ocular inflammatory conditions, dry eye diseases, or abnormal corneal neovascularization.

The present invention relates to an oil-in-water microemulsion which has been proved to be a suitable drug depot system for the treatment of anterior ocular diseases, wherein the disease is selected from the group consisting of corneal neovascularization disease (NV), ocular melanoma, gel-drop corneal dystrophy (GDLD), secondary corneal amyloidosis-GDLD type, Graves eye disease, Szifen syndrome (SJS), silkworm-erosive corneal ulceration and corneal transplant rejection, more particularly neovascularization disease (NV). The microemulsion according to the present invention is indeed capable of efficiently delivering and maintaining a high concentration of an active ingredient in the anterior segment of the eye after administration.

The invention discloses application of a binuclear manganese complex to treatment and / or prevention of corneal neovascular diseases, and the binuclear manganese complex has excellent catalytic activity, can catalyze hydrogen peroxide to generate a large amount of oxygen, and can inhibit neovascularization.

This invention discloses siRNAs that target and inhibit ZEB1 gene expression and their applications, belonging to the field of biomedical technology. The siRNAs designed in this invention that target and inhibit ZEB1 gene expression include siRNA1-2913, siRNA2-652, and siRNA3-1073. The sense and antisense strands of siRNA1-2913 are shown in SEQ ID NO:1-2, the sense and antisense strands of siRNA2-652 are shown in SEQ ID NO:3-4, and the sense and antisense strands of siRNA3-1073 are shown in SEQ ID NO:5-6. These siRNAs can efficiently inhibit ZEB1 gene expression, inhibit the proliferation and migration of vascular endothelial cells, and intervene in the formation of pathological corneal neovascularization. They can be used for research on the pathogenesis and intervention of corneal neovascularization, showing very promising application prospects.

The present invention belongs to the field of eye drops. In view of the problem that the existing diclofenac sodium ophthalmic preparations have poor efficacy and strong irritation on corneal neovascularization, the present invention provides a method for preparing diclofenac sodium eye drops. First, under ice bath conditions, a diclofenac solution is added to a ferrous sulfate solution. Subsequently, proanthocyanidins are coordinated with ferrous sulfate and diclofenac sodium to obtain an iron-based proanthocyanidin-diclofenac sodium nanozyme. The present invention obtains an iron-based proanthocyanidin-diclofenac sodium nanozyme by coordinating proanthocyanidins, ferrous sulfate and diclofenac sodium. The nanozyme is used for eye drops, which improves the inhibitory effect of diclofenac eye drops on corneal neovascularization, and can improve corneal sensitivity and maintain normal intraocular pressure.

The present invention relates to compounds useful for treating diseases or conditions associated with excessive vascularization of the eye, such as corneal neovascularization, iris neovascularization, ciliary body neovascularization, corneal pannus, choroidal neovascularization, retinal neovascularization, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.

The present invention provides a ROS-responsive micelle-gel complex for treating corneal neovascularization and a preparation method, providing a new ocular drug delivery strategy. The excellent neovascular endothelial cell targeting and corneal adhesion of this hypotonic micelle-gel complex enable efficient and specific drug delivery to the diseased area and sustained release, thereby maintaining the therapeutic concentration required by the eye. It can significantly extend the drug release cycle, reduce patient compliance, and improve the clinical treatment effect of corneal neovascularization. This non-invasive drug administration method can also avoid the many ocular complications and toxic side effects brought to patients by invasive injection methods. The strong adhesion properties of the hypotonic gel itself also ensure that the drug remains in the diseased area for a long time, greatly improving the absorption and utilization of the therapeutic drug by the eye.

The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation of the ciliary body, corneal pannus, choroidal neovascularisation, retinal neovascularisation, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.

The invention discloses a corneal neovascularization automatic quantitative analysis and grading method, system and terminal based on image processing. The problems that in the existing corneal neovascularization evaluation process, a complete automatic technical system from image input, blood vessel segmentation to clinical quantitative scoring is lacked, a large amount of manual intervention is needed in the actual process, and high-efficiency and standardized automatic evaluation cannot be achieved are mainly solved. The invention provides a corneal neovascularization automatic quantitative analysis and grading method, system and terminal based on image processing, and provides a set of end-to-end automatic analysis system to realize a complete process of automatic CoNV segmentation, quantitative analysis and clinical structured scoring, so that the objectivity, consistency and efficiency of CoNV evaluation can be effectively improved, and the method and system are suitable for popularization and application. The obvious clinical application value and popularization potential are realized.

A hydrogel preparation for ultra-fast sutureless closure of corneal perforations, as well as its preparation method and application, has the advantages of simple preparation, mild and controllable gelation conditions, rapid gelation, good shape adaptability, high transparency, and strong bioadhesion. It can achieve ultra-fast sutureless closure of corneal perforations, maintain the integrity of the anterior chamber of the eye, significantly reduce corneal neovascularization, and improve corneal transparency. In addition, the hydrogel can be loaded with multiple drugs to effectively inhibit corneal stromal fibrosis and prevent corneal scarring.

The present application provides compositions and methods for treatment of ocular inflammatory conditions, dry eye diseases, and abnormal corneal neovascularization, using etiprednol. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, propylene glycol diacetate (PGD), a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, phenethyl alcohol, ethanol, isopropanol, glycerol, propylene glycol, polyethylene glycol, n-butanol, or combinations thereof. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of ocular inflammatory conditions, dry eye diseases, or abnormal corneal neovascularization.

The invention provides a gRNA, an AAV expression vector and a CRISPR / Cas9 system for treating corneal neovascular diseases, and particularly provides a composition which comprises: (a) a gene editing protein or an expression vector thereof, the gene editing protein comprising type II Cas protein; the gene editing protein comprises (a) a gene editing protein and (b) gRNA or an expression vector thereof, the gRNA guides the gene editing protein to be specifically combined with DNA of a VEGFA gene, a gRNA targeting area is an exon 1 of a VEGFA gene sequence, and the combination of the gRNA specifically targeting the exon 1 of the VEGFA gene sequence and the gene editing protein can effectively prevent and / or treat corneal neovascularization diseases.

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

To provide dosing regimens for angiogenic eye disorders, particularly regimens that allow less frequent dosing while maintaining high levels of efficacy.SOLUTION: The present invention provides a method of treating an angiogenic eye disorder by sequentially administering multiple dosing of a VEGF antagonist to a patient. The method comprises administering to the patient multiple dosing of the VEGF antagonist at a frequency of once every 8 weeks or once every more weeks. The method is useful for treating angiogenic eye disorders such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and corneal neovascularization.SELECTED DRAWING: None

The invention provides application of an NCOA3 polyQ structural domain in preparation of a medicine for relieving ocular vascular abnormal hyperplasia diseases, relates to the technical field of biomedicine, and aims to solve the problems that in the prior art, an ocular pathological angiogenesis mechanism is complex, and safe and effective targeted intervention means are lacked. The construction of a mouse corneal micropocket pathological angiogenesis model proves that Nco3polyQ structural domain deletion can significantly inhibit corneal neovascularization: compared with a WT mouse, the Nco3wt / Q mouse corneal tissue CD31 positive signal is reduced, the number of corneal neovascularization in the Nco3Q / Q mouse is minimum, and the CD31 positive area is minimum; meanwhile, qPCR (quantitative polymerase chain reaction) detection of corneal tissues shows that mRNA (messenger ribonucleic acid) expression of the vascular marker genes Pecam1 and Cdh5 is in a decreasing trend and is further decreased in an Nco3Q / Q mouse. On the basis, the intervention strategy aiming at the NCOA3 polyQ structural domain is used for preparing the medicine for relieving the abnormal hyperplasia diseases of the ocular blood vessels, and a new treatment strategy and a potential target are provided for related diseases of the ophthalmology department.

Methods of treating choroidal neovascularization in a patient in need thereof are described herein. In some aspects, the method comprises inhibiting telomerase activity within a biological compartment of the patient. In some instances, inhibiting telomerase activity comprises disposing a telomerase inhibitor and / or disposing an antisense oligonucleotide within the biological compartment of the patient. In some embodiments, the biological compartment of the patient is the eye. Further, in some instances, the patient has neovascular age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity (ROP), corneal neovascularization, and / or neovascular glaucoma.

The present application belongs to the field of biomedical technology. More specifically, the present application relates to a polypeptide, a polypeptide composition and a pharmaceutical composition comprising the polypeptide, and the present application also relates to the use of the polypeptide and the polypeptide composition in the preparation of a pharmaceutical composition. Whether in vivo or in vitro, KV-7A exhibits a stronger therapeutic effect than KV-7, especially in the treatment of diseases related to corneal neovascularization. Therefore, the KV-7A of the present application has a wide range of application potential.

The invention relates to the technical field of biological medicines, in particular to nanoparticles as well as a preparation method and application thereof. The invention provides the nano-particles prepared by taking a thiol compound as an antibody carrier material, the permeation efficiency of the antibody in eyes is remarkably improved by the nano-particles through a thiol exchange pathway, and the antibody can reach deep tissues of the eyes through eye drop administration, such as cornea, cornea, cornea and the like. The nano-particle delivery system can be enriched in eye posterior tissues such as retina and choroids, and the nano-particle delivery system shows a good treatment effect in corneal neovascularization eye diseases and uveitis.

The present invention relates to an oil-in-water microemulsion that has shown to be a suitable drug depot system for the treatment of disorders of the anterior segment of the eye, wherein said disease is selected from the group consisting of corneal neovascularization disease (NV), ocular melanoma, Gelatinous drop-like corneal dystrophy (GDLD), Secondary corneal amyloidosis—GDLD type, Graves ophthalmopathy, Stevens-Johnson syndrome (SJS), Mooren's ulcer, and Corneal graft rejection and more particularly of neovascularization disease (NV). The microemulsion according to the invention is indeed capable of effectively delivering and maintaining on the anterior segment of the eye high concentrations of active ingredients after administration.

This invention provides a complex based on neutrophil nanovesicles that combines anti-inflammatory and anti-angiogenic bidirectional trapping with autoluminescent dynamics, along with its preparation method and applications, belonging to the field of biopharmaceutical manufacturing technology. The complex uses neutrophil nanovesicles as a carrier and also encapsulates bis(2,4,5-trichlorosalicylate n-amyl)oxalate (CPPO) and the photosensitizer Ce6. Simultaneously, the surface is modified with ranibizumab via ROS-responsive ketothiols. The complex possesses the characteristics of trapping anti-inflammatory factors and spontaneously targeting corneal neovascularization lesions. Based on ROS-responsive release of ranibizumab to bind vascular endothelial growth factor, it exerts an anti-angiogenic function. Simultaneously, the chemical energy generated by CPPO under hyperoxia conditions excites Ce6 to produce singlet oxygen, thereby inhibiting the tubular formation ability of vascular endothelial cells. This invention provides a new approach for the treatment of eye-related diseases.

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

The present invention discloses a contact lens care solution for inhibiting corneal hypoxia and corneal neovascularization. The solution contains the following ingredients: withaferin A, disodium edetate, a solubilizing agent, a thickener, an antibacterial agent, an isotonicity regulator, and an appropriate amount of a pH regulator, with the remainder being water for injection. The solution specifically comprises the following steps: first, weighing withaferin A and a solubilizing agent, mixing them, and stirring them thoroughly for later use; second, weighing the above-mentioned weight-to-volume ratio of disodium edetate, a thickener, a pH regulator, an isotonicity regulator, and an antibacterial agent, heating and stirring the mixture in a 60°C water bath until clear and translucent, and then cooling to room temperature; third, adding the mixture from the first step to the solution from the second step, and adjusting the volume with water for injection to obtain a contact lens care solution; and fourth, filtering the obtained care solution through a 0.22 μm microporous membrane for sterilization and aseptically packaging. The solution has good solubility, improves corneal tissue hypoxia and corneal neovascularization caused by contact lens wear, and provides preventive and health benefits.

Disclosed is use of a dinuclear manganese complex in treating and / or preventing a corneal neovascular disease. The dinuclear manganese metal complex exhibits excellent catalytic activity. It can catalyze the generation of a large amount of oxygen from hydrogen peroxide and can inhibit neovascularization.

The invention relates to application of a TWEAK-TWEAKR signal channel as a target spot in preparation of a medicine for treating corneal injury, and belongs to the technical field of biology. According to the invention, a TWEAK-TWEAKR signal channel is utilized, and in corneal injury, the blocking drug of the signal channel is adopted to block the TWEAK-TWEAKR signal channel, so that abnormal expression of related genes after corneal injury can be inhibited, corneal inflammatory response and corneal neovascularization can be inhibited, and corneal injury can be effectively treated.

The invention relates to a hydrogel preparation for sutureless ultrafast sealing of corneal perforation injury and a preparation method and application thereof, the hydrogel preparation has the advantages of simple preparation, mild and controllable gelling condition, fast gelling, good shape adaptability, high transparency, strong biological adhesion and the like, the ultrafast sutureless sealing of corneal perforation injury is realized, the integrity of anterior chamber of the eye is maintained, and the healing of the corneal perforation injury is facilitated. The hydrogel can effectively inhibit corneal stroma fibrosis, obviously reduce corneal neovascularization and improve corneal transparency, can load various drugs, and can effectively inhibit corneal stroma fibrosis and prevent corneal scars.

A contact lens care solution for inhibiting corneal hypoxia injury and corneal neovascularization. The contact lens care solution comprises the following components: withaferin A, disodium edetate, a solubilizer, a thickener, an antimicrobial agent, a tonicity adjuster, and a pH-adjusting agent in an appropriate amount, with the balance being water for injection. The preparation method specifically comprises the following steps: step 1: weighing withaferin A and a solubilizer, mixing and thoroughly stirring same until a uniform mixed solution is obtained for later use; step 2: weighing disodium edetate, a thickener, a pH-adjusting agent, a tonicity adjuster and an antimicrobial agent in the weight-to-volume ratio, heating same in a water bath at 60°C under stirring until a clear and transparent solution is obtained, and then cooling the solution to room temperature; step 3: adding the mixed solution from step 1 to the solution from step 2, and making up to the volume with water for injection to prepare a contact lens care solution; and step 4: sterilizing the prepared care solution by means of filtration through a 0.22 μm microporous filter membrane, and performing aseptic packaging. The contact lens care solution has a good solubility, can alleviate corneal tissue hypoxia and corneal neovascularization caused by contact lens wear, and exhibits preventive and health-care effects.